The Netherlands Cancer Institute: Prostatic Neoplasms trials

The registry lists 19 Prostatic Neoplasms studies with The Netherlands Cancer Institute as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 3Phase 3 2Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two FractionsRecruitingNCT07391982Not applicable
• PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)RecruitingNCT06875258Phase 4
• Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)RecruitingNCT06691776Not applicable
• The Diagnostic Value of FAPI PET/CT in Staging of Newly Diagnosed Prostate CancerNot yet recruitingNCT06634173Not applicable
• Image-guided Navigation During Robotic Sentinel Node RemovalRecruitingNCT06091072Not applicable
• Tracer-Guided Surgery for Recurrent Prostate CancerRecruitingNCT05555017Phase 2
• The Prognostic Role of Lymph Node Dissection In Men With Prostate Cancer Treated With Radical ProstatectomyRecruitingNCT05109910Not applicable
• A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRLCompletedNCT06284304Not applicable
• Standard Moderately Hypofractionated RT vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate CancerActive, not recruitingNCT05705921Not applicable
• CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid TumoursCompletedNCT05518799Not applicable
• EBRT + Lu-PSMA for N1M0 Prostate CancerCompletedNCT05162573Phase 1
• Multispectral Fluorescence as a Tool to Separate Healthy and Disease Related Lymphatic Anatomies in Prostate Cancer.CompletedNCT05120973
• Technetium Based Radioguided Surgery for Prostate Cancer (TRACE) StudyStatus unknownNCT03857113
• Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen AblationCompletedNCT03297385Phase 2
• Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With DocetaxelCompletedNCT03295565Phase 2/3
• Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223CompletedNCT03223727
• Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223CompletedNCT03223597
• Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate CancerTerminatedNCT03066154Phase 1
• Radiotherapy for Prostate Cancer: Conventional Dose Versus High DoseCompletedNCT00692107Phase 3